Approximately 50%–65% of patients with EGFR-mutated lung adenocarcinoma will acquire resistance within 1 year despite initial response to TKI therapy, and eventually die of this disease [6]; thus, a more accurate prediction tool is currently an imperative need. This evidence concerns the gene EGFR and lung adenocarcinoma.